Papillomavirus genome structure, expression, and post-transcriptional regulation

Frontiers in Bioscience

Volumn 11, Issue SUPPL. 1, 2006, Pages 2286-2302

  Zheng, Zhi Ming ^a,b   Baker, Carl C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NONE   (United States)

Author keywords

Gene Expression; Papillomaviruses; Posttranscriptional Regulation; Review; RNA Polyadenylation; RNA Splicing

Indexed keywords

CANCER VIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; PAPILLOMAVIRIDAE;

EID: 33744756020     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/1971     Document Type: Review

References (153)

1. E. M. de Villiers, C. Fauquet, T. R. Broker, H. U. Bernard & H. H. zur Hausen, Classification of papillomaviruses, Virology 324, 17-27 (2004)
2. E. Y. Chen, P. M. Howley, A. D. Levinson & P. H. Seeburg, The primary structure and genetic organization of the bovine papillomavirus type 1 genome, Nature 299, 529-534 (1982)
3. O. Danos, M. Katinka & M. Yaniv, Human papillomavirus 1a complete DNA sequence: a novel type of genome organization among papovaviridae, EMBO J. 1, 231-236 (1982)
4. N. Munoz, F. X. Bosch, S. de Sanjose, R. Herrero, X. Castellsague, K. V. Shah, P. J. Snijders & C. J. Meijer, Epidemiologic classification of human papillomavirus types associated with cervical cancer, N.Engl.J.Med. 348, 518-527 (2003)
5. J. T. Schiller & P. Davies, Delivering on the promise: HPV vaccines and cervical cancer, Nat.Rev.Microbiol. 2, 343-347 (2004)
6. D. R. Lowy & I. H. Frazer, Chapter 16: Prophylactic human papillomavirus vaccines, J.Natl.Cancer Inst.Monogr 111-116 (2003)
7. K. S. Cuschieri & H. A. Cubie, The role of human papillomavirus testing in cervical screening, J.Clin.Virol. 32 Suppl 1, S34-S42 (2005)
8. A. Molijn, B. Kleter, W. Quint & L. J. van Doorn, Molecular diagnosis of human papillomavirus (HPV) infections, J.Clin.Virol. 32 Suppl 1, S43-S51 (2005)
9. K. Munger & P. M. Howley, Human papillomavirus immortalization and transformation functions, Virus Res. 89, 213-228 (2002)
10. P. F. Lambert, B. A. Spalholz & P. M. Howley, A transcriptional represser encoded by BPV-1 shares a common carboxy-terminal domain with the E2 transactivator, Cell 50, 69-78 (1987)
11. N. L. Hubbert, J. T. Schiller, D. R. Lowy & E. J. Androphy, Bovine papilloma virus-transformed cells contain multiple E2 proteins, Proc.Natl.Acad.Sci.U.S.A 85, 5864-5868 (1988)
12. J. Choe, P. Vaillancourt, A. Stenlund & M. Botchan, Bovine papillomavirus type 1 encodes two forms of a transcriptional repressor: structural and functional analysis of new viral cDNAs, J.Virol. 63, 1743-1755 (1989)
13. F. Stubenrauch, M. Hummel, T. Iftner & L. A. Laimins, The E8E2C protein, a negative regulator of viral transcription and replication, is required for extrachromosomal maintenance of human papillomavirus type 31 in keratinocytes, J.Virol. 74, 1178-1186 (2000)
14. F. Stubenrauch, T. Zobel & T. Iftner, The E8 domain confers a novel long-distance transcriptional repression activity on the E8E2C protein of high-risk human papillomavirus type 31, J.Virol. 75, 4139-4149 (2001)
15. J. B. Harry & F. O. Wettstein, Transforming properties of the cottontail rabbit papillomavirus oncoproteins Le6 and SE6 and of the E8 protein, J.Virol. 70, 3355-3362 (1996)
16. R. Han, N. M. Cladel, C. A. Reed & N. D. Christensen, Characterization of transformation function of cottontail rabbit papillomavirus E5 and E8 genes, Virology 251, 253-263 (1998)
17. H. U. Bernard, Gene expression of genital human papillomaviruses and considerations on potential antiviral approaches, Antivir.Ther. 7, 219-237 (2002)
18. C. C. Baker & C. Calef, Maps of papillomavirus mRNA transcripts, in "The human papillomaviruses compendium" (Los Alamos National Laboratory, Ed.), Los Alamos National Laboratory, (1995)
19. M. A. Ozbun & C. Meyers, Two novel promoters in the upstream regulatory region of human papillomavirus type 31b are negatively regulated by epithelial differentiation, J.Virol. 73, 3505-3510 (1999)
20. M. A. Ozbun, Human papillomavirus type 31b infection of human keratinocytes and the onset of early transcription, J.Virol. 76, 11291-11300 (2002)
21. E. Sen, S. Alam & C. Meyers, Genetic and biochemical analysis of cis regulatory elements within the keratinocyte enhancer region of the human papillomavirus type 31 upstream regulatory region during different stages of the viral life cycle, J. Virol. 78, 612-629 (2004)
22. W. Deng, G. Jin, B. Y. Lin, B. A. Van Tine, T. R. Broker & L. T. Chow, mRNA splicing regulates human papillomavirus type 11 E1 protein production and DNA replication, J. Virol. 77, 10213-10226 (2003)
23. D. Smotkin & F. O. Wettstein, Transcription of human papillomavirus type 16 early genes in a cervical cancer and a cancer-derived cell line and identification of the E7 protein, Proc.Natl.Acad.Sci.U.S.A 83, 4680-4684 (1986)
24. K. Grassmann, B. Rapp, H. Maschek, K. U. Petry & T. Iftner, Identification of a differentiation-inducible promoter in the E7 open reading frame of human papillomavirus type 16 (HPV-16) in raft cultures of a new cell line containing high copy numbers of episomal HPV-16 DNA, J. Virol. 70, 2339-2349 (1996)
25. M. W. Rosenstierne, J. Vinther, C. N. Hansen, M. Prydsoe & B. Norrild, Identification and characterization of a cluster of transcription start sites located in the E6 ORF of human papillomavirus type 16, J.Gen.Virol. 84, 2909-2920 (2003)
26. M. A. Ozbun & C. Meyers, Characterization of late gene transcripts expressed during vegetative replication of human papillomavirus type 31b, J. Virol. 71, 5161-5172 (1997)
27. M. Hummel, J. B. Hudson & L. A. Laimins, Differentiation-induced & constitutive transcription of human papillomavirus type 31b in cell lines containing viral episomes, J. Virol. 66, 6070-6080 (1992)
28. A. Schneider-Gadicke & E. Schwarz, Different human cervical carcinoma cell lines show similar transcription patterns of human papillomavirus type 18 early genes, EMBOJ. 5, 2285-2292 (1986)
29. F. Thierry, J. M. Heard, K. Dartmann & M. Yaniv, Characterization of a transcriptional promoter of human papillomavirus 18 and modulation of its expression by simian virus 40 and adenovirus early antigens, J. Virol. 61, 134-142 (1987)
30. H. Romanczuk, F. Thierry & P. M. Howley, Mutational analysis of cis elements involved in E2 modulation of human papillomavirus type 16 P97 and type 18 P105 promoters, J. Virol. 64, 2849-2859 (1990)
31. E. J. Androphy, D. R. Lowy & J. T. Schiller, Bovine papillomavirus E2 trans-activating gene product binds to specific sites in papillomavirus DNA, Nature 325, 70-73 (1987)
32. P. Hawley-Nelson, E. J. Androphy, D. R. Lowy & J. T. Schiller, The specific DNA recognition sequence of the bovine papillomavirus E2 protein is an E2-dependent enhancer, EMBO J. 1, 525-531 (1988)
33. R. Sousa, N. Dostatni & M. Yaniv, Control of papillomavirus gene expression, Biochim.Biophys.Acta 1032, 19-37 (1990)
34. S. Y. Hou, S. Y. Wu, T. Zhou, M. C. Thomas & C. M. Chiang, Alleviation of human papillomavirus E2-mediated transcriptional repression via formation of a TATA binding protein (or TFIID)-TFIIB-RNA polymerase II-TFIIF preinitiation complex, Mol.Cell Biol. 20, 113-125 (2000)
35. V. Bechtold, P. Beard & K. Raj, Human papillomavirus type 16 E2 protein has no effect on transcription from episomal viral DNA, J. Virol 77, 2021-2028 (2003)
36. Z. M. Zheng, M. Tao, K. Yamanegi, S. Bodaghi & W. Xiao, Splicing of a Cap-proximal Human Papillomavirus 16 E6E7 Intron Promotes E7 Expression, but can be Restrained by Distance of the Intron from its RNA 5′ Cap, J.Mol.Biol. 337, 1091-1108 (2004)
37. R. M. Ordonez, A. M. Espinosa, D. J. Sanchez-Gonzalez, J. Armendariz-Borunda & J. Berumen, Enhanced oncogenicity of Asian-American human papillomavirus 16 is associated with impaired E2 repression of E6/E7 oncogene transcription, J. Gen. Virol. 85, 1433-1444 (2004)
38. X. Zhao, D. Oberg, M. Rush, J. Fay, H. Lambkin & S. Schwartz, A 57-nucleotide upstream early polyadenylation element in human papillomavirus type 16 interacts with hFipl, CstF-64, hnRNP C1/C2, and polypyrimidine tract binding protein, J.Virol. 79, 4270-4288 (2005)
39. J. Doorbar, A. Parton, K. Hartley, L. Banks, T. Crook, M. Stanley & L. Crawford, Detection of novel splicing patterns in a HPV-16-containing keratinocyte cell line, Virology 178, 254-262 (1990)
40. L. Sherman, N. Alloul, I. Golan, M. Durst & A. Baram, Expression and splicing patterns of human papillomavirus type-16 mRNAs in pre-cancerous lesions and carcinomas of the cervix, in human keratinocytes immortalized by HPV 16, and in cell lines established from cervical cancers, Int. J. Cancer 50, 356-364 (1992)
41. L. Sherman & N. Alloul, Human papillomavirus type 16 expresses a variety of alternatively spliced mRNAs putatively encoding the E2 protein, Virology 191, 953-959 (1992)
42. S. Tang, K. Yamanegi & Z. M. Zheng, Requirement of a 12-base-pair TATT-containing sequence and viral lyric DNA replication in activation of the Kaposi's sarcoma-associated herpesvirus K8.1 late promoter, J.Virol. 78, 2609-2614 (2004)
43. E. J. Wade & D. H. Spector, The human cytomegalovirus origin of DNA replication (oriLyt) is the critical cis-acting sequence regulating replication-dependent late induction of the viral 1.2-kilobase RNA promoter, J. Virol. 68, 6567-6577 (1994)
44. M. Hummel, H. B. Lim & L. A. Laimins, Human papillomavirus type 31b late gene expression is regulated through protein kinase C-mediated changes in RNA processing, J. Virol. 69, 3381-3388 (1995)
45. J. M. Bodily & C. Meyers, Genetic analysis of the human papillomavirus type 31 differentiation-dependent late promoter, J. Virol. 79, 3309-3321 (2005)
46. K. M. Spink & L. A. Laimins, Induction of the human papillomavirus type 31 late promoter requires differentiation but not DNA amplification, J. Virol. 79, 4918-4926 (2005)
47. S. K. Barksdale & C. C. Baker, Differentiation-specific expression from the bovine papillomavirus type 1 P2443 and late promoters, J. Virol. 67, 5605-5616 (1993)
48. O. Danos, M. Katinka & M. Yaniv, Molecular cloning, refined physical map and heterogeneity of methylan'on sites of papilloma virus type 1a DNA, Eur.J.Biochem. 109, 457-461 (1980)
49. F. O. Wettstein & J. G. Stevens, Shope papilloma virus DNA is extensively methylated in non-virus-producing neoplasms, Virology 126, 493-504 (1983)
50. T. S. Burnett & J. P. Sleeman, Uneven distribution of methylation sites within the human papillomavirus 1a genome: possible relevance to viral gene expression, Nucleic Acids Res. 12, 8847-8860 (1984)
51. F. Rosl, A. Arab, B. Klevenz & H. H. zur, The effect of DNA methylation on gene regulation of human papillomaviruses, J. Gen. Virol. 74 (Pt 5), 791-801 (1993)
52. K. B. Choo, L. N. Liew, S. J. Liew & W. T. Cheng, Hypermethylation of the human papillomavirus transgenome in transgenic mice, Proc.Natl.Sci.Counc. Repub.China B 17, 159-163 (1993)
53. H. J. List, V. Patzel, U. Zeidler, A. Schopen, G. Ruhl, J. Stollwerk & G. Klock, Methylation sensitivity of the enhancer from the human papillomavirus type 16, J.Biol.Chem. 269, 11902-11911 (1994)
54. A. Thain, O. Jenkins, A. R. Clarke & K. Gaston, CpG methylation directly inhibits binding of the human papillomavirus type 16 E2 protein to specific DNA sequences, J. Virol 70, 7233-7235 (1996)
55. V. Badal, L. S. Chuang, E. H. Tan, S. Badal, L. L. Villa, C. M. Wheeler, B. F. Li & H. U. Bernard, CpG methylation of human papillomavirus type 16 DNA in cervical cancer cell lines and in clinical specimens: genomic hypomethylation correlates with carcinogenic progression, J. Virol. 77, 6227-6234 (2003)
56. S. Badal, V. Badal, I. E. Calleja-Macias, M. Kalantari, L. S. Chuang, B. F. Li & H. U. Bernard, The human papillomavirus-18 genome is efficiently targeted by cellular DNA methylation, Virology 324, 483-492 (2004)
57. K. Kim, P. A. Garner-Hamrick, C. Fisher, D. Lee & P. F. Lambert, Methylation patterns of papillomavirus DNA, its influence on E2 function, and implications in viral infection, J.Virol. 77, 12450-12459 (2003)
58. B. A. Van Tine, J. C. Kappes, N. S. Banerjee, J. Knops, L. Lai, R. D. Steenbergen, C. L. Meijer, P. J. Snijders, P. Chatis, T. R. Broker, P. T. Moen, Jr. & L. T. Chow, Clonal selection for transcriptionally active viral oncogenes during progression to cancer, J. Virol. 78, 11172-11186 (2004)
59. M. Kalantari, I. E. Calleja-Macias, D. Tewari, B. Hagmar, K. Lie, H. A. Barrera-Saldana, D. J. Wiley & H. U. Bernard, Conserved methylation patterns of human papillomavirus type 16 DNA in asymptomatic infection and cervical neoplasia, J. Virol. 78, 12762-12772 (2004)
60. D. J. Wiley, J. Huh, J. Y. Rao, C. Chang, M. Goetz, M. Poulter, E. Masongsong, C. I. Chang & H. U. Bernard, Methylation of human papillomavirus genomes in cells of anal epithelia of HIV-infected men, J.Acquir.Immune.Defic. Syndr. 39, 143-151 (2005)
61. Q. Feng, A. Balasubramanian, S. E. Hawes, P. Toure, P. S. Sow, A. Dem, B. Dembele, C. W. Critchlow, L. Xi, H. Lu, M. W. McIntosh, A. M. Young & N. B. Kiviat, Detection of hypermethylated genes in women with and without cervical neoplasia, J.Natl.Cancer Inst. 97, 273-282 (2005)
62. J. Zhang, C. R. Martins, Z. B. Fansler, K. L. Roemer, E. A. Kincaid, K. S. Gustafson, D. F. Heitjan & D. P. Clark, DNA methylation in anal intraepithelial lesions and anal squamous cell carcinoma, Clin. Cancer Res. 11, 6544-6549 (2005)
63. 62a. J.R. Sanford, J. Ellis & J. F. Caceres: Multiple roles of arginine/serine-rich splicing factors in RNA processing. Biochem Soc Trans. 33:443-446 (2005).
64. Z. M. Zheng, Regulation of alternative RNA splicing by exon definition and exon sequences in viral and Mammalian gene expression, J.Biomed.Sci. 11, 278-294 (2004)
65. A. N. Ladd & T. A. Cooper, Finding signals that regulate alternative splicing in the post-genomic era, Genome Biol. 3, reviews0008 (2002)
66. S. Barksdale & C. C. Baker, Differentiation-specific alternative splicing of bovine papillomavirus late mRNAs, J.Virol. 69, 6553-6556 (1995)
67. Z. M. Zheng, P. He & C. C. Baker, Selection of the bovine papillomavirus type 1 nucleotide 3225 3′ splice site is regulated through an exonic splicing enhancer and its juxtaposed exonic splicing suppressor, J.Virol. 70, 4691-4699 (1996)
68. Z. M. Zheng, P. J. He & C. C. Baker, Structural, functional, and protein binding analyses of bovine papillomavirus type 1 exonic splicing enhancers, J.Virol. 71, 9096-9107 (1997)
69. Z. M. Zheng, M. Huynen & C. C. Baker, A pyrimidine-rich exonic splicing suppressor binds multiple RNA splicing factors and inhibits spliceosome assembly, Proc.Natl.Acad.Sci.U.S.A 95, 14088-14093 (1998)
70. Z. M. Zheng, P. J. He & C. C. Baker, Function of a bovine papillomavirus type 1 exonic splicing suppressor requires a suboptimal upstream 3′ splice site, J.Virol. 73, 29-36 (1999)
71. Z. M. Zheng, J. Quintero, E. S. Reid, C. Gocke & C. C. Baker, Optimization of a weak 3′ splice site counteracts the function of a bovine papillomavirus type 1 exonic splicing suppressor in vitro and in vivo, J.Virol. 74, 5902-5910 (2000)
72. Z. M. Zheng, E. S. Reid & C. C. Baker, Utilization of the bovine papillomavirus type 1 late-stage-specific nucleotide 3605 3′ splice site is modulated by a novel exonic bipartite regulator but not by an intronic purine-rich element, J.Virol. 74, 10612-10622 (2000)
73. M. Rush, X. Zhao & S. Schwartz, A splicing enhancer in the E4 coding region of human papillomavirus type 16 is required for early mRNA splicing and polyadenylation as well as inhibition of premature late gene expression, J.Virol. 79, 12002-12015 (2005)
74. X. Zhao, M. Rush & S. Schwartz, Identification of an hnRNP A1-dependent splicing silencer in the human papillomavirus type 16 L1 coding region that prevents premature expression of the late L1 gene, J.Virol. 78, 10888-10905 (2004)
75. D. Smotkin, H. Prokoph & F. O. Wettstein, Oncogenic and nononcogenic human genital papillomaviruses generate the E7 mRNA by different mechanisms, J.Virol. 63, 1441-1447 (1989)
76. S. A. Sedman, M. S. Barbosa, W. C. Vass, N. L. Hubbert, J. A. Haas, D. R. Lowy & J. T. Schiller, The full-length E6 protein of human papillomavirus type 16 has transforming and trans-activating activities and cooperates with E7 to immortalize keratinocytes in culture, J. Virol. 65, 4860-4866 (1991)
77. W. G. Hubert & L. A. Laimins, Human papillomavirus type 31 replication modes during the early phases of the viral life cycle depend on transcriptional and posttranscriptional regulation of E1 and E2 expression, J.Virol. 76, 2263-2273 (2002)
78. F. Chen, C. C. MacDonald & J. Wilusz, Cleavage site determinants in the mammalian polyadenylation signal, Nucleic Acids Res. 23, 2614-2620 (1995)
79. K. Ryan, O. Calvo & J. L. Manley, Evidence that polyadenylation factor CPSF-73 is the mRNA 3′ processing endonuclease, RNA 10, 565-573 (2004)
80. M. H. Stoler, S. M. Wolinsky, A. Whitbeck, T. R. Broker & L. T. Chow, Differentiation-linked human papillomavirus types 6 and 11 transcription in genital condylomata revealed by in situ hybridization with message-specific RNA probes, Virology 172, 331-340 (1989)
81. P. A. Furth & C. C. Baker, An element in the bovine papillomavirus late 3′ untranslated region reduces polyadenylated cytoplasmic RNA levels, J. Virol. 65, 5806-5812 (1991)
82. I. M. Kennedy, J. K. Haddow & J. B. Clements, Analysis of human papillomavirus type 16 late mRNA 3′ processing signals in vitro and in vivo, J. Virol. 64, 1825-1829 (1990)
83. P. A. Furth, W. T. Choe, J. H. Rex, J. C. Byrne & C. C. Baker, Sequences homologous to 5′ splice sites are required for the inhibitory activity of papillomavirus late 3′ untranslated regions, Mol.Cell Biol. 14, 5278-5289 (1994)
84. S. I. Gunderson, M. Polycarpou-Schwarz & I. W. Mattaj, U1 snRNP inhibits pre-mRNA polyadenylation through a direct interaction between U1 70K and poly(A) polymerase, Mol.Cell 1, 255-264 (1998)
85. B. Ko & S. I. Gunderson, Identification of new poly(A) polymerase-inhibitory proteins capable of regulating pre-mRNA polyadenylation, J.Mol.Biol. 318, 1189-1206 (2002)
86. P. Fortes, Y. Cuevas, F. Guan, P. Liu, S. Pentlicky, S. P. Jung, M. L. Martinez-Chantar, J. Prieto, D. Rowe & S. I. Gunderson, Inhibiting expression of specific genes in mammalian cells with 5′ end-mutated U1 small nuclear RNAs targeted to terminal exons of pre-mRNA, Proc.Natl.Acad.Sci.U. S.A 100, 8264-8269 (2003)
87. S. A. Gumming, M. G. McPhillips, T. Veerapraditsin, S. G. Milligan & S. V. Graham, Activity of the human papillomavirus type 16 late negative regulatory element is partly due to four weak consensus 5′ splice sites that bind a U1 snRNP-like complex, J. Virol. 77, 5167-5177 (2003)
88. W. Dietrich-Goetz, I. M. Kennedy, B. Levins, M. A. Stanley & J. B. Clements, A cellular 65-kDa protein recognizes the negative regulatory element of human papillomavirus late mRNA, Proc.Natl.Acad.Sci.U.S.A 94, 163-168 (1997)
89. M. D. Koffa, S. V. Graham, Y. Takagaki, J. L. Manley & J. B. Clements, The human papillomavirus type 16 negative regulatory RNA element interacts with three proteins that act at different posttranscriptional levels, Proc.Natl.Acad.Sci.U.S.A 97, 4677-4682 (2000)
90. M. G. McPhillips, T. Veerapraditsin, S. A. Cumming, D. Karali, S. G. Milligan, W. Boner, I. M. Morgan & S. V. Graham, SF2/ASF binds the human papillomavirus type 16 late RNA control element and is regulated during differentiation of virus-infected epithelial cells, J. Virol. 78, 10598-10605 (2004)
91. S. A. Cumming, C. E. Repellin, M. McPhillips, J. C. Radford, J. B. Clements & S. V. Graham, The human papillomavirus type 31 late 3′ untranslated region contains a complex bipartite negative regulatory element, J.Virol. 76, 5993-6003 (2002)
92. C. C. Baker & J. S. Noe, Transcriptional termination between bovine papillomavirus type 1 (BPV-1) early and late polyadenylation sites blocks late transcription in BPV-1-transformed cells, J. Virol. 63, 3529-3534 (1989)
93. S. Buratowski, Connections between mRNA 3′ end processing and transcription termination, Curr.Opin.Cell Biol. 17, 257-261 (2005)
94. E. M. &rews & D. DiMaio, Hierarchy of polyadenylation site usage by bovine papillomavirus in transformed mouse cells, J. Virol. 67, 7705-7710 (1993)
95. S. S. Terhune, W. G. Hubert, J. T. Thomas & L. A. Laimins, Early polyadenylation signals of human papillomavirus type 31 negatively regulate capsid gene expression, J. Virol. 75, 8147-8157 (2001)
96. S. S. Terhune, C. Milcarek & L. A. Laimins, Regulation of human papillomavirus type 31 polyadenylation during the differentiation-dependent life cycle, J.Virol. 73, 7185-7192 (1999)
97. D. Oberg, J. Fay, H. Lambkin & S. Schwartz, A downstream polyadenylation element in human papillomavirus type 16 L2 encodes multiple GGG motifs and interacts with hnRNP H, J. Virol. 79, 9254-9269 (2005)
98. I. Kaufmann, G. Martin, A. Friedlein, H. Langen & W. Keller, Human Fip1 is a subunit of CPSF that binds to U-rich RNA elements and stimulates poly(A) polymerase, EMBO J. 23, 616-626 (2004)
99. C. Le Sommer, M. Lesimple, A. Mereau, S. Menoret, M. R. Allo & S. Hardy, PTB regulates the processing of a 3′-terminal exon by repressing both splicing and polyadenylation, Mol. Cell Biol. 25, 9595-9607 (2005)
100. G. K. Arhin, M. Boots, P. S. Bagga, C. Milcarek & J. Wilusz, Downstream sequence elements with different affinities for the hnRNP H/H′ protein influence the processing efficiency of mammalian polyadenylation signals, Nucleic Acids Res. 30, 1842-1850 (2002)
101. I. M. Kennedy, J. K. Haddow & J. B. Clements, A negative regulatory element in the human papillomavirus type 16 genome acts at the level of late mRNA stability, J.Virol. 65, 2093-2097 (1991)
102. W. Tan & S. Schwartz, The Rev protein of human immunodeficiency virus type 1 counteracts the effect of an AU-rich negative element in the human papillomavirus type 1 late 3′ untranslated region, J. Virol. 69, 2932-2945 (1995)
103. M. Sokolowski, C. Zhao, W. Tan & S. Schwartz, AU-rich mRNA instability elements on human papillomavirus type 1 late mRNAs and c-fos mRNAs interact with the same cellular factors, Oncogene 15, 2303-2319 (1997)
104. B. Collier, D. Oberg, X. Zhao & S. Schwartz, Specific inactivation of inhibitory sequences in the 5′ end of the human papillomavirus type 16 L1 open reading frame results in production of high levels of L1 protein in human epithelial cells, J. Virol. 76, 2739-2752 (2002)
105. W. Tan, B. K. Felber, A. S. Zolotukhin, G. N. Pavlakis & S. Schwartz, Efficient expression of the human papillomavirus type 16 L1 protein in epithelial cells by using Rev and the Rev-responsive element of human immunodeficiency virus or the cis-acting transactivation element of simian retrovirus type 1, J.Virol. 69, 5607-5620 (1995)
106. M. Sokolowski, W. Tan, M. Jellne & S. Schwartz, mRNA instability elements in the human papillomavirus type 16 L2 coding region, J. Virol. 72, 1504-1515 (1998)
107. B. Collier, L. Goobar-Larsson, M. Sokolowski & S. Schwartz, Translational inhibition in vitro of human papillomavirus type 16 L2 mRNA mediated through interaction with heterogenous ribonucleoprotein K and poly (rC)-binding proteins 1 and 2, J.Biol.Chem. 273, 22648-22656 (1998)
108. D. Oberg, B. Collier, X. Zhao & S. Schwartz, Mutational inactivation of two distinct negative RNA elements in the human papillomavirus type 16 L2 coding region induces production of high levels of L2 in human cells, J. Virol. 77, 11674-11684 (2003)
109. C. De Pasquale & D. Kanduc, Modulation of HPV-16 E7 translation by tRNAs in eukaryotic cell-free translation systems, Biochem.Mol.Biol.Int. 45, 1005-1009 (1998)
110. J. Zhou, W. J. Liu, S. W. Peng, X. Y. Sun & I. Frazer, Papillomavirus capsid protein expression level depends on the match between codon usage and tRNA availability, J. Virol. 73, 4972-4982 (1999)
111. W. Gu, M. Li, W. M. Zhao, N. X. Fang, S. Bu, I. H. Frazer & K. N. Zhao, tRNASer (CGA) differentially regulates expression of wild-type and codon-modified papillomavirus L1 genes, Nucleic Acids Res. 32, 4448-4461 (2004)
112. K. N. Zhao, W. Gu, N. X. Fang, N. A. Saunders & I. H. Frazer, Gene codon composition determines differentiation-dependent expression of a viral capsid gene in keratinocytes in vitro and in vivo, Mol. Cell Biol. 25, 8643-8655 (2005)
113. K. N. Zhao, W. J. Liu & I. H. Frazer, Codon usage bias and A+T content variation in human papillomavirus genomes, Virus Res. 98, 95-104 (2003)
114. G. L. Disbrow, I. Sunitha, C. C. Baker, J. Hanover & R. Schlegel, Codon optimization of the HPV-16 E5 gene enhances protein expression, Virology 311, 105-114 (2003)
115. W. J. Liu, F. Gao, K. N. Zhao, W. Zhao, G. J. Fernando, R. Thomas & I. H. Frazer, Codon modified human papillomavirus type 16 E7 DNA vaccine enhances cytotoxic T-lymphocyte induction and anti-tumour activity, Virology 301, 43-52 (2002)
116. A. Cid-Arregui, V. Juarez & H. H. zur, A synthetic E7 gene of human papillomavirus type 16 that yields enhanced expression of the protein in mammalian cells and is useful for DNA immunization studies, J.Virol. 77, 4928-4937 (2003)
117. C. Leder, J. A. Kleinschmidt, C. Wiethe & M. Muller, Enhancement of capsid gene expression: preparing the human papillomavirus type 16 major structural gene L1 for DNA vaccination purposes, J. Virol. 75, 9201-9209 (2001)
118. D. Baud, F. Ponci, M. Bobst, P. De Grandi & D. Nardelli-Haefliger, Improved efficiency of a Salmonella-based vaccine against human papillomavirus type 16 virus-like particles achieved by using a codon-optimized version of L1, J.Virol. 78, 12901-12909 (2004)
119. N. Mossadegh, L. Gissmann, M. Muller, H. Zentgraf, A. Alonso & P. Tomakidi, Codon optimization of the human papillomavirus 11 (HPV 11) L1 gene leads to increased gene expression and formation of virus-like particles in mammalian epithelial cells, Virology 326, 57-66 (2004)
120. S. N. Stacey, D. Jordan, A. J. Williamson, M. Brown, J. H. Coote & J. R. Arrand, Leaky scanning is the predominant mechanism for translation of human papillomavirus type 16 E7 oncoprotein from E6/E7 bicistronic mRNA, J. Virol. 74, 7284-7297 (2000)
121. M. Remm, A. Remm & M. Ustav, Human papillomavirus type 18 E1 protein is translated from polycistronic mRNA by a discontinuous scanning mechanism, J. Virol. 73, 3062-3070 (1999)
122. D. Kanduc, Translational regulation of human papillomavirus type 16 E7 mRNA by the peptide SEQIKA, shared by rabbit alpha (1)-globin and human cytokeratin 7, J. Virol. 76, 7040-7048 (2002)
123. D. M. von Knebel, T. Oltersdorf, E. Schwarz & L. Gissmann, Correlation of modified human papilloma virus early gene expression with altered growth properties in C4-1 cervical carcinoma cells, Cancer Res. 48, 3780-3786 (1988)
124. D. M. von Knebel, C. Rittmuller, H. H. zur & M. Durst, Inhibition of tumorigenicity of cervical cancer cells in nude mice by HPV E6-E7 anti-sense RNA, Int. J.Cancer 51, 831-834 (1992)
125. C. Steele, L. M. Cowsert & E. J. Shillitoe, Effects of human papillomavirus type 18-specific antisense oligonucleotides on the transformed phenotype of human carcinoma cell lines, Cancer Res. 53, 2330-2337 (1993)
126. T. M. Tan & R. C. Ting, In vitro and in vivo inhibition of human papillomavirus type 16 E6 and E7 genes, Cancer Res. 55, 4599-4605 (1995)
127. S. Alam, J. Bromberg-White, M. McLaughlin-Drubin, E. Sen, J. M. Bodily & C. Meyers, Activity and therapeutic potential of ORI-1001 antisense oligonucleotide on human papillomavirus replication utilizing a model of dysplastic human epithelium, Anticancer Res. 25, 765-777 (2005)
128. G. A. Clawson, G. Q. Miranda, A. Sivarajah, P. Xin, W. Pan, D. Thiboutot & N. D. Christensen, Inhibition of papilloma progression by antisense oligonucleotides targeted to HPV-11HPV-11 E6/E7 RNA, Gene Ther. 11, 1331-1341 (2004)
129. Y. He & L. Huang, Growth inhibition of human papillomavirus 16 DNA-positive mouse tumor by antisense RNA transcribed from U6 promoter, Cancer Res. 57, 3993-3999 (1997)
130. N. K. Vaish, A. R. Kore & F. Eckstein, Recent developments in the hammerhead ribozyme field, Nucleic Acids Res. 26, 5237-5242 (1998)
131. J. D. Wisotzkey, A. Krizenoskas, S. DiAngelo & J. W. Kreider, Cleavage of cottontail rabbit papillomavirus E7 RNA with an anti-E7 ribozyme, Biochem.Biophys.Res.Comrmm. 192, 833-839 (1993)
132. Y. K. He, C. D. Lu & G. R. Qi, In vitro cleavage of HPV-16 E6 and E7 RNA fragments by synthetic ribozymes and transcribed ribozymes from RNA-trimming plasmids, FEBS Lett. 322, 21-24 (1993)
133. D. Lu, S. Chatterjee, D. Brar & K. K. Wong, Jr., Ribozyme-mediated in vitro cleavage of transcripts arising from the major transforming genes of human papillomavirus type 16, Cancer Gene Ther. 1, 267-277 (1994)
134. Z. Chen, P. Kamath, S. Zhang, M. M. Weil & E. J. Shillitoe, Effectiveness of three ribozymes for cleavage of an RNA transcript from human papillomavirus type 18, Cancer Gene Ther. 2, 263-271 (1995)
135. M. J. Fedor, The catalytic mechanism of the hairpin ribozyme, Biochem.Soc.Trans. 30, 1109-1115 (2002)
136. Y. Lian, M. B. De Young, A. Siwkowski, A. Hampel & J. Rappaport, The sCYMV1 hairpin ribozyme: targeting rules and cleavage of heterologous RNA, Gene Ther. 6, 1114-1119 (1999)
137. L. M. Alvarez-Salas, A. E. Cullinan, A. Siwkowski, A. Hampel & J. A. DiPaolo, Inhibition of HPV-16 E6/E7 immortalization of normal keratinocytes by hairpin ribozymes, Proc.Natl.Acad.Sci.U.S.A 95, 1189-1194 (1998)
138. G. J. Hannon & J. J. Rossi, Unlocking the potential of the human genome with RNA interference, Nature 431, 371-378 (2004)
139. M. Jiang & J. Milner, Selective silencing of viral gene expression in HPV-positive human cervical carcinoma cells treated with siRNA, a primer of RNA interference, Oncogene 21, 6041-6048 (2002)
140. K. Butz, T. Ristriani, A. Hengstermann, C. Denk, M. Scheffher & F. Hoppe-Seyler, siRNA targeting of the viral E6 oncogene efficiently kills human papillomavirus-positive cancer cells, Oncogene 22, 5938-5945 (2003)
141. Tang, S., Tao, M., McCoy, J. P., Jr., & Zheng, Z. M. Short-term induction and long-term suppression of HPV-16 oncogene silencing by RNA interference in cervical cancer cells. Doi:10.1038/sj.onc.1209244, Oncogene December 12 (2005)
142. A. H. Hall & K. A. Alexander, RNA interference of human papillomavirus type 18 E6 and E7 induces senescence in HeLa cells, J. Virol. 77, 6066-6069 (2003)
143. M. Yoshinouchi, T. Yamada, M. Kizaki, J. Fen, T. Koseki, Y. Ikeda, T. Nishihara & K. Yamato, In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by E6 siRNA, Mol.Ther. 8, 762-768 (2003)
144. L. G. Mitchell & G. J. McGarrity, Gene therapy progress and prospects: reprograming gene expression by trans-splicing, Gene Ther. 12, 1477-1485 (2005)
145. Patrick, M., Puttaraju, M., DiPasquale, J., Quintero, J., Yang, Y., Garcia-Blanco, M. A., Mitchell, L. G., & Baker, C. C. Factors that influence spliceosome mediated RNA trans-splicing efficacy. Mol. Ther. in press. 2006.
146. D. M. Harper, E. L. Franco, C. Wheeler, D. G. Ferris, D. Jenkins, A. Schuind, T. Zahaf, B. Innis, P. Naud, N. S. De Carvalho, C. M. Roteli-Martins, J. Teixeira, M. M. Blatter, A. P. Korn, W. Quint & G. Dubin, Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial, Lancet 364, 1757-1765 (2004)
147. L. L. Villa, R. L. Costa, C. A. Petta, R. P. Andrade, K. A. AuIt, A. R. Giuliano, C. M. Wheeler, L. A. Koutsky, C. Malm, M. Lehtinen, F. E. Skjeldestad, S. E. Olsson, M. Steinwall, D. R. Brown, R. J. Kurman, B. M. Ronnett, M. H. Stoler, A. Ferenczy, D. M. Harper, G. M. Tamms, J. Yu, L. Lupinacci, R. Railkar, F. J. Taddeo, K. U. Jansen, M. T. Esser, H. L. Sings, A. J. Saah & E. Barr, Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial, Lancet Oncol. 6, 271-278 (2005)
148. L. A. Koutsky, K. A. Ault, C. M. Wheeler, D. R. Brown, E. Barr, F. B. Alvarez, L. M. Chiacchierini & K. U. Jansen, A controlled trial of a human papillomavirus type 16 vaccine, N.Engl.J.Med. 347, 1645-1651 (2002)
149. M. C. Lai, B. H. Teh & W. Y. Tarn, A human papillomavirus E2 transcriptional activator. The interactions with cellular splicing factors and potential function in pre-mRNA processing, J.Biol.Chem. 274, 11832-11841 (1999)
150. P. D. Zamore & B. Haley, Ribo-gnome: the big world of small RNAs, Science 309, 1519-1524 (2005)
151. I. Alvarez-Garcia & E. A. Miska, MicroRNA functions in animal development and human disease, Development 132, 4653-4662 (2005)
152. K. Middleton, W. Peh, S. Southern, H. Griffin, K. Sotlar, T. Nakahara, A. El Sherif, L. Morris, R. Seth, M. Hibma, D. Jenkins, P. Lambert, N. Coleman & J. Doorbar, Organization of human papillomavirus productive cycle during neoplastic progression provides a basis for selection of diagnostic markers, J. Virol. 77, 10186-10201 (2003)
153. X. Liu, A. Mayeda, M. Tao & Z. M. Zheng, Exonic splicing enhancer-dependent selection of the bovine papillomavirus type 1 nucleotide 3225 3′ splice site can be rescued in a cell lacking splicing factor ASF/SF2 through activation of the phosphatidylinositol 3-kinase/Akt pathway, J. Virol. 77, 2105-2115 (2003)